Business Model Breakdown
How Uniqure NV Makes Money
QURE
Market Cap
$1.1B
Annual Revenue
$16M
Profit Margin
-1236.0%
Employees
209
The Short Version
uniQure NV is a biopharmaceutical company focused on developing and commercializing gene therapies for patients suffering from serious genetic diseases. They primarily generate revenue through milestones and royalties from their approved gene therapy, Hemgenix, which is commercialized by CSL Behring. Additionally, they invest heavily in research and development to advance their pipeline of gene therapies, with AMT-130 for Huntington's disease being their lead investigational product, aiming for future direct product sales upon successful regulatory approval.
Where the Revenue Comes From
Hemgenix royalties and milestone payments (~100% of current reported revenue)
Potential future product sales (e.g., AMT-130, currently investigational)
Who buys: Primarily CSL Behring (for Hemgenix distribution); ultimately patients with rare genetic diseases like Huntington's Disease and Hemophilia B (through licensed products or future direct sales).
Why It Works (Competitive Advantages)
- ✔Proprietary AAV5 gene therapy platform
- ✔Approved gene therapy product (Hemgenix) validating technology
- ✔Focus on rare, severe diseases with high unmet need
Economic Moat: Narrow (Intangible Assets/IP (proprietary AAV5 vector technology, gene therapy pipeline patents))
What Our Analysis Says
DVR Score as of April 28, 2026
uniQure's previous 10x potential, primarily tied to AMT-130 for Huntington's disease, has been severely hampered by recent developments. The FDA's criticism of the study design, requiring additional studies and delaying the BLA submission, coupled with multiple securities class-action lawsuits, represents a significant setback. While the long-term market opportunity for gene therapy in rare diseases remains, the execution risk and timeline uncertainty for its lead candidate have dramatically increased. Financials show a concerning -40.6% YoY revenue decline and a deeply negative, worsening net margin. The cash runway, previously into H1 2027, is now a more pressing concern, potentially necessitating future dilution. The established AAV5 platform and Hemgenix royalties provide a foundational base, but the primary growth catalyst is now in jeopardy, leading to a substantial downgrade in the overall score. Institutional buying provides some offset, but the legal and regulatory headwinds are paramount.